1 completed, 1 recruiting, 1 terminated. 3 Phase 1.
By phase and status
Follow Cholangiocarcinoma, Extrahepatic: new trials by email Literature Review of Cholangiocarcinoma, Extrahepatic trials Research Report on Cholangiocarcinoma, Extrahepatic
Trials (filtered) newest first · largest first
All 3 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine - Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic | Phase 1 | Recruiting | 18 | 2026-05-01 | 2026-05-29 |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
LMB-100, Tofacitinib, Mesothelin Expression - Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma | Phase 1 | Completed | 19 | 2019-08-29 | 2023-08-01 |
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | 85 | 2017-10-02 | 2020-02-07 |
Narrower conditions
Cholangiocarcinoma (3) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Gallbladder Neoplasms (1) · Klatskin Tumor (1)
Broader conditions
Carcinoma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Biliary Tract Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gallbladder Diseases (1) · Neoplasms by Site (1)
Interventions
Cyclophosphamide (1) · LMB-100 (1) · PEGPH20 (1) · atezolizumab (1) · fludarabine (1) · tofacitinib (1)
Sponsors
Halozyme Therapeutics (1) · National Cancer Institute (NCI) (1) · Shanghai Zhongshan Hospital (1)
Countries
United States (2) · China (1) · South Korea (1) · Thailand (1)
Top investigators
Christine C Alewine, M.D. (1) · Guoming Shi, MD, PhD (1)
Results publications
PMID 38706610